- Home
- AEON vs AIMD Comparison
AEON vs AIMD Comparison
Compare AEON & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | AIMD |
|---|---|---|
| Founded | N/A | 1984 |
| Country | United States | United States |
| Employees | 8 | 41 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 17.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEON | AIMD |
|---|---|---|
| Price | $0.64 | $2.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.20 | N/A |
| AVG Volume (30 Days) | 35.6K | ★ 889.9K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.45 |
| 52 Week High | $1.45 | $4.50 |
Technical Indicators
Market Signals| Indicator | AEON | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 45.97 |
| Support Level | $0.65 | $1.80 |
| Resistance Level | $1.12 | $2.51 |
| Average True Range (ATR) | 0.05 | 0.24 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 57.04 | 7.46 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About AIMD Ainos Inc.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.